Oscullo G, Bekki A, de la Rosa D, Martinez-García M A
Servicio de Neumología e Instituto de Investigación La Fe (IISLAFE), Hospital Universitario y Politécnico La Fe, Valencia, Spain;, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain;, Pneumology Department, Santa Cre i Sant Pau Hospital, Barcelona, Spain.
Int J Tuberc Lung Dis. 2025 May 25;29(5):199-201. doi: 10.5588/ijtld.25.0157.
Until relatively recently, bronchiectasis (not due to cystic fibrosis) was considered an orphan disease, lacking clinical and commercial interest, and was rarely diagnosed. Since the 2000s, several working groups have emerged in Europe and the US - with the first register for bronchiectasis launching in Spain - and these have demonstrated the impact bronchiectasis has on health. Today, bronchiectasis is considered the third most common chronic inflammatory disease of the airways, after COPD and asthma, and represents a significant economic burden. We make the case for further characterization of these registries to better understand the heterogeneous epidemiology of bronchiectasis.
直到最近，支气管扩张症（非囊性纤维化所致）还被视为一种罕见病，缺乏临床和商业关注度，很少被诊断出来。自21世纪以来，欧洲和美国出现了几个工作组——西班牙率先启动了首个支气管扩张症登记处——这些都证明了支气管扩张症对健康的影响。如今，支气管扩张症被认为是继慢性阻塞性肺疾病（COPD）和哮喘之后第三常见的气道慢性炎症性疾病，并且带来了巨大的经济负担。我们主张进一步对这些登记处进行特征描述，以便更好地了解支气管扩张症的异质性流行病学。
